A NOVEL DNA VACCINE PLATFORM WITH THE POTENTIAL TO CREATE NEXT-GENERATION VACCINES

A NOVEL DNA VACCINE PLATFORM WITH THE POTENTIAL TO CREATE NEXT-GENERATION VACCINES
© 2022 IMUNON Inc. PAGE 1 PLACCINE Nucleic Acid Vaccine Platform P L A C C I N E : A N o v e l D N A V a c c i n e P l a t f o r m w i t h P o t e n t i a l t o C r e a t e N e x t G e n e r a t i o n V a c c i n e s Vaccine Technology Summit March 20-21, 2023 Cambridge, Massachusetts, USA K h u r s h e e d A n w e r
© 2022 IMUNON Inc. PAGE 2 PLACCINE – A Novel DNA Vaccine Platform Key Attributes Multi-valent Durable Novel Formulation Flexible Design Multiple antigens in a single plasmid DNA Breadth of Immune Responses Durable antigen expression/nAB & T-cell responses Independent of virus, device, or LNPs “Plug & Play”, rapid Manufacturing Stable at Workable Temp > 9 months stability at > 4o C Broad-spectrum immunity, durable nAB and T-cell responses, protection, longer shelf-life at workable temp, and flexible manufacturing warrants PLACCINE as potential alternative to current vaccines
© 2022 IMUNON Inc. PAGE 3 Expression Vector Optional Immune modifier DNA Antigen DNA 1 Antigen DNA 2 PLACCINE pDNA Constructs PLACCINE Delivery Systems PLACCINE Vaccines -Synthetic Delivery Systems • Non-viral • Non-device Intramuscular (IM) Administration Nanoparticles/Complexes Humoral & Cell Mediated Immune Response Potential Administration Routes • Subcutaneous (SC) • Intradermal (ID) • Intranasal (IN) Transcription elements & backbone sequence Up to 4 genes have been successfully incorporated and expressed PLACCINE Technology Platform Multicistronic or Single Antigen Vector Formulations Independent of Virus or Device
© 2022 IMUNON Inc. PAGE 4 mRNA • Short-lived responses requiring frequent boosts • Poor stability at working temperatures Protein • Manufacturing challenges • Poor cytolytic T-cell responses pDNA Well-suited to overcome these Limitations • Longer duration of antigen expression/exposure • Strong T-cell responses • Stability at > 4O C pDNA limitation: Insufficient delivery relying on viruses or devices (e.g., electroporation, jet) Current Vaccines Despite some Success have Significant Limitations PLACCINE Technology to Potentially Address these Limitations PLACCINE Approach • Leveraging the DNA advantages (multi-cistronic, durability, CD8 response, shelf-life) • Delivery without virus or device to achieve better safety and compliance
© 2022 IMUNON Inc. PAGE 5 A PLACCINE Formulation for Intramuscular Delivery without a Device/Virus Early Antigen Expression (24 hr) and Bio-distribution in Mouse Muscle Tissue (day 7) 10 to 15-Fold Improvement over naked DNA 105 106 107 108 21-025 intensity Luciferase (RLU/mg protein) Naked DNA PLACCINE Formulation Lot#1 Lot#2 21-025
© 2022 IMUNON Inc. PAGE 6 Chien KR Cold Spring Harb Perspect Med 2015;5:a014035 PLACCINE Formulation ay 1 D ay 3 D ay 7 D ay 14 D ay 21 D ay 28 D ay 35 D ay 42 D ay 56 22-014 PBS pVac-Luc/CP/AlPO4 pVac-Luc-S/CP/AlPO4 PBS pVac-Luc Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42Day 56 Day 85 102 103 104 105 106 107 108 Average Radiance [p/s/cm 2 /sr] PBS pVac-Luc/CP/AlPO4 pDNA Yields More Durable Antigen Expression than the Protein or Modified mRNA
© 2022 IMUNON Inc. PAGE 7 • DNA vector pVac-9 (Spike-D614G) • Formulation PLACCINE • 125 mg DNA PBS CP/pVac9 Naked/pVac9 CP/pVac 13 101 102 103 104 105 Endpoint Titer Day 14 Day 35 Day 14 Day 35 PLACCINE Naked DNA Naked DNA PBS PBS T-cell Response (IFN-g) Day 35 PLACCINE PLACCINE Formulation Yields Higher Immunogenicity than Naked pDNA IgG Titer Endpoint Titer Balb/c mice
© 2022 IMUNON Inc. PAGE 8 Immunogenicity of Single Antigen PLACCINE Vectors - IgG and nAB titers Viral Mutation Warrants Vaccine Effectiveness Against Multiple Variants • Optimized vectors pVac-15 (D614G), pVac-16 (Delta) • Formulation: PLACCINE including an adjuvant • 125 mg DNA IgG Titer (day 35 after prime) PBS pVac15 (125) pVac16 (125) pVac17 (125) mRNA 2P (1ug) 102 103 104 105 106 Endpoint Titer Day 35 PBS pVac-15 pVac-16 mRNA Vaccine pVac-17 D614G Delta D614G +Delta D614 SARS-CoV-2 Variant IgG Titer (day 35 after prime) PBS pVac15 (125) pVac16 (125) pVac17 (125) mRNA 2P (1ug) Day 35 PBS pVac-15 pVac-16 mRNA Vaccine pVac-17 D614G Delta D614G +Delta D614 S-CoV-2 Variant 10 2 D614G Delta IgG Titer- Day 35 Variant Antigen pVac15(125) pVac16(125) pVac17(125) mRNA2P 1 2 3 4 D614G LV Groups IC50 Titer All groups with CP/Alum pVac15(125) pVac16(125) pVac17(125) mRNA2P 1 2 3 4 Delta LV Groups IC50 Titer All groups with CP/Alum pVac-15 pVac-16 pVac-16 pVac-15 D614G Variant Delta Variant D614G Delta D614G Delta Neutralizing Antibody Titer- Day 35 (pseudovirus competition assay) Variant Antigen Variant Antigen Balb/c mice
© 2022 IMUNON Inc. PAGE 9 pVac15(125) pVac16(125) pVac17(125) mRNA2P 1 2 3 4 Delta LV Groups IC50 Titer All groups with CP/Alum pVac15(125) pVac16(125) pVac17(125) mRNA2P 1 2 3 4 Delta LV Groups IC50 Titer All groups with CP/Alum neutralization against D614G variant neutralization against Delta variant pVac-17 pVac-17mRNA benchmark mRNA Benchmark D614G Variant Delta Variant Immunogenicity of a Multi-variant PLACCINE Vaccine A Bivalent Vaccine is Well Suited for a Mutating Virus IgG Titer ay 35 after prime) PBS pVac15 (125) pVac16 (125) pVac17 (125) mRNA 2P (1ug) Day 35 PBS pVac-15 pVac-16 mRNA Vaccine pVac-17 D614G Delta D614G +Delta D614 V-2 Variant IgG Titer (day 35 after prime) PBS pVac15 (125) pVac16 (125) pVac17 (125) mRNA 2P (1ug) 102 103 104 105 106 Endpoint Titer Day 35 PBS pVac-15 pVac-16 mRNA Vaccine pVac-17 D614G Delta D614G +Delta D614 SARS-CoV-2 Variant pVac-17 PBS mRNA benchmark • Multicistronic vector pVac-17 (D614G-Delta) • Formulation: PLACCINE including an adjuvant • 125 mg DNA D614G-Delta D614 D614G-Delta Wuhan D614G-Delta Wuhan IgG Titer (Day 35) Variant Antigen Variant Antigen Variant Antigen nAb (Day 35) Balb/c mice
© 2022 IMUNON Inc. PAGE 10 pVac15 pVac17 Placebo pVac16 pVac17 Placebo TCID50/gm of lung • pVac-15 (D614G), pVac-16 (Delta), pVac-17 (D614G-Delta) • Formulation: PLACCINE including an adjuvant • Dose - 125 mg DNA, Day-1, 21 103 104 105 106 107 103 104 105 106 Delta Challenge - 7 X 104 LOD LOD TCID 50 /gm of lung D614G Challenge- 2.5 X 106 PLACCINE Vaccines Provide Protection Against Viral Challenge hACE2:K18 Mouse Model- 7 days post challenge
© 2022 IMUNON Inc. PAGE 11 PLACCINE-induced T-cell Responses are Associated with Increases in CD8+ Cells Population in Spleenocytes • Vectors: pVac-16 (Delta), pVac-17 (D614G+Delta) • Formulation: PLACCINE • 125 mg DNA • Pseudo-typed lentivirus assay pVac-17 pVac-54 pVac17 pVac54 0 500 1000 1500 23-003 IFNγ T cells SFC/10 6 cells SFC/10 6 Cells 23-003 T-cell Response (IFN-g) TNF-a IFN-g PBS pVac17 pVac54 0.0 0.2 0.4 0.6 0.8 CD8 S1 peptide pool CD8+ Tcells (%) TNFa IFNy pVac-17 pVac-54 CD8+ T-cells (%) PBS CD8 T-cells
© 2022 IMUNON Inc. PAGE 12 PBS mRNA pVac50 102 103 104 105 Endpoint Titer 2wkp1 4wkp1 5wkp1 PBS mRNA pVac50 0 100 200 300 400 500 SFC/10 6 cells Single Dose PLACCINE Vs mRNA Vaccine Better Immune Quality with PLACCINE IgG Response T-cell Response (IFN-g) Additional Studies on Immune Quality Comparison are in Progress
© 2022 IMUNON Inc. PAGE 13 • Vectors: pVac-16 (Delta), pVac-17 (D614G+Delta) • Formulation: PLACCINE including an adjuvant • 125 mg DNA • Pseudo-typed lentivirus assay for nAb PLACCINE Vaccines Provide Durable Neutralizing Antibody Response >12-months Durability in Mice nAb (Delta) Responses 0 1 2 3 4 pVac16 pVac17 mRNA2P IC50 Titer 2 Months 3 Months 5 Months 6 Months 1 Month 8 Months ✱✱ 0 1 2 3 4 pVac16 pVac17 mRNA2P IC50 Titer 2 Months 3 Months 5 Months 6 Months 1 Month 8 Months ✱✱ PBS pVac15 pVac16 pVac17 mRNA 0 200 400 600 800 22-002 (No boost) SFC/10 6 cells PBS pVac15 pVac16 pVac17 mRNA 0 200 400 600 800 22-002 (No boost) SFC/10 6 cells pVac-15 pVac-16 mRNA PBS T-cell Response (IFN-g) 8-months data 12-months data
© 2022 IMUNON Inc. PAGE 14 PLACCINE Induces Robust Immune Response after a Single Injection Wistar Institute Collaboration Group Antigen pVax N/A pVAC50 (125ug) Delta spike-Immunon pVAC50 (50ug) Delta spike-Immunon pVAC50 (25ug) Delta spike-Immunon 0 25 50 125 Dose mg 0 25 50 125 Dose mg 0 25 50 125 Dose mg
© 2022 IMUNON Inc. PAGE 15 PLACCINE Vaccines are Immunogenic in Cynomolgus Monkeys PLACCINE Subjects Showed IgG and Neutralizing Antibody Response • Single antigen vector: pVac-15 (D614G) or pVac-16 (DELTA) • Comparator mRNA: Commercial mRNA Vaccine (LNP) • Formulation: PLACCINE including an adjuvant • Dosing schedule: Day 1, 28, 84 Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 101 102 103 104 105 106 Endpoint Titer 7wkp2 3wkp3 Day 0 4wkp2 Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 101 102 103 104 105 106 Endpoint Titer 7wkp2 3wkp3 Day 0 4wkp2 IgG Titer * The second booster was pVac-16 at 2 mg dose *
© 2022 IMUNON Inc. PAGE 16 • Single antigen vector pVac-15 (D614G) in PLACCINE • Comparator mRNA Commercial mRNA Vaccine (LNP) • Dosing schedule Day 1, 28, 84 • nAB titer Day 105 (21 days after 3rd dose) Neutralizing Antibody Titers in PLACCINE-Vaccinated Cynomolgus Monkeys 90% of PLACCINE Subjects Showed Neutralizing Ab Response nAb Titer * * The second booster was pVac-16 at 2 mg dose Placebo 1mg pvac15 2mg pvac16 5mg+1mg pvac15+pvac16 100ug mRNA 101 102 103 104 105 NHP Plaque Reduction Neutralization Assay Titer IC 50 4wkp2 3wkp3 7d post-challenge
© 2022 IMUNON Inc. PAGE 17 PLACCINE Vaccines Provide Complete Protection Against Viral Challenge Comparable Efficacy to a Commercial mRNA Vaccine- Challenge dose: 1 x 106 TCID50 Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) Bronchoalveolar Lavage Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) 1 2 3 4 5 6 Log copies/ml 7 Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Nasal Swab (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 Log copies/ml Nasal Swab (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) 5 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copie Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Bronchoalveolar Lavage (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) bo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copie Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) bo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA Bronchoalveolar Lavage (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/m Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/m Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/m Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Bronchoalveolar Lavage (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ml Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ml Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 2 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 4 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ml Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 Log copies/ml Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 7 after challenge) Placebo 1mg pvac15 2mg pvac16 5mg pvac15 5mg+1mg pvac15+pvac16 100ug mRNA 1 2 3 4 5 6 7 Log copies/ml Bronchoalveolar Lavage (Day 2 after challenge) Nasal Swab Bronchoalveolar Lavage Log Copies/ml Log Copies/ml 2 Days after Challenge 4 Days after Challenge 7 Days after Challenge Placebo pVac-15 (1, 1 mg) pVac-16 (2, 2 mg) pVac-15 (5, 1 mg) mRNA (100, 100 mg) Prime and boost vaccination qRT-PCR
© 2022 IMUNON Inc. PAGE 18 <2.7 means below the lower limit of detection Vaccine Bronchoalveolar lavage Nasal swab Day-2 Day-4 Day -7 Day-2 Day-4 Day -7 Placebo 6.20 3.20 5.20 4.37 4.37 <2.7 3.70 <2.7 <2.7 5.37 6.37 5.20 4.70 5.20 5.70 4.20 3.70 3.37 pVac 15 (1mg) <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 4.70 <2.7 <2.7 <2.7 4.20 5.37 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 pVAC16 (2 mg) <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 pVac-15/pVac-16 (5mg, 1mg) <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 mRNA (100ug) <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 <2.7 PLACCINE Vaccines Provide Complete Protection Against Viral Challenge Comparable Efficacy to a Commercial mRNA Vaccine- Challenge dose: 1 x 106 TCID50 TCID50 Assay
© 2022 IMUNON Inc. PAGE 19 PLACCINE 4⁰C Storage Months 1 3 6 9 12 • Vector: pVac-17 (D614G-Delta) • Formulation: PLACCINE PLACCINE is Stable at 4⁰C for at Least 9 Months Immunogenicity studies in Mice Fresh 4o C Fresh 4C 4C (ALPO4 fresh) 102 103 104 105 Endpoint Titer IgG Response 1 month 3 month 6 month 9 month
© 2022 IMUNON Inc. PAGE 20 Robust nAb & T-cell responses Durable & broad-spectrum Immunity Longer shelf-life at workable temperature Flexible design for rapid production Summary PLACCINE, A Potential Alternative to Current Vaccine Approaches
© 2022 IMUNON Inc. PAGE 21 T h a n k Yo u

Check these out next

A NOVEL DNA VACCINE PLATFORM WITH THE POTENTIAL TO CREATE NEXT-GENERATION VACCINES

Recommandé

Contenu connexe

Similaire à A NOVEL DNA VACCINE PLATFORM WITH THE POTENTIAL TO CREATE NEXT-GENERATION VACCINES(20)

Plus de iQHub(20)

Dernier(20)

A NOVEL DNA VACCINE PLATFORM WITH THE POTENTIAL TO CREATE NEXT-GENERATION VACCINES